Liebe HTA-Interessierte,

wir freuen uns, Sie darauf hinweisen zu dürfen, dass folgende neue Berichte bzw. Updates (online) veröffentlicht wurden:

Oncology Factsheets (Updates):

• Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Update February 2022. Oncology Fact Sheet Nr. 60.
• Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma. Update February 2022. Oncology Fact Sheet Nr. 63.
• Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC). Update February 2022. Oncology Fact Sheet Nr. 64.
• Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima®) for the treatment of advanced or recurrent endometrial carcinoma (EC). Update February 2022. Oncology Fact Sheet Nr. 68.

Jahresbericht:

• AIHTA-Jahresbericht 2021

Mit freundlichen Grüßen
Ozren Sehic
______________________________________________________________________________

Ozren Sehic, M.A.
Assistenz der Geschäftsführung und Wissenschaftskommunikation
Austrian Institute for Health Technology Assessment
Garnisongasse 7/20, 1090 Vienna
Tel: +43 (0) 1 236 81 19-23
Webseite